Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (171-180 of 186) with videos related to

Pageof 19
Sort By:
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Cancer Research|March 3, 2017
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast CancerJuan M Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
The New England Journal of Medicine|December 3, 2010
Adjuvant docetaxel for high-risk, node-negative breast cancerMiguel Martín, Miguel A Seguí, Antonio Antón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 studyMiguel Martín, Amparo Ruiz, Manuel Ruiz Borrego, et al.
Current Cancer Drug Targets|August 18, 2015
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient ProfileAntonio González-Martín, Emilio Alba, Eva Ciruelos, et al.
Breast Cancer Research and Treatment|January 14, 2014
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER studyEduardo Martínez de Dueñas, Ana Lluch Hernández, Angel Guerrero Zotano, et al.
Nature Cell Biology|April 21, 2018
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancerSylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, et al.
Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
JAMA|May 12, 2011
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancerChristos Hatzis, Lajos Pusztai, Vicente Valero, et al.
Cancer Research|May 14, 2009
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristicsBryan T Hennessy, Ana-Maria Gonzalez-Angulo, Katherine Stemke-Hale, et al.
Cancer Research|March 3, 2017
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast CancerJuan M Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, et al.
NPJ Breast Cancer|April 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancerLillian M Smyth, Gerald Batist, Funda Meric-Bernstam, et al.
The Journal of Clinical Investigation|June 24, 2020
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseSusana Garcia-Recio, Aatish Thennavan, Michael P East, et al.
The New England Journal of Medicine|December 3, 2010
Adjuvant docetaxel for high-risk, node-negative breast cancerMiguel Martín, Miguel A Seguí, Antonio Antón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 studyMiguel Martín, Amparo Ruiz, Manuel Ruiz Borrego, et al.
Current Cancer Drug Targets|August 18, 2015
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient ProfileAntonio González-Martín, Emilio Alba, Eva Ciruelos, et al.
Breast Cancer Research and Treatment|January 14, 2014
Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER studyEduardo Martínez de Dueñas, Ana Lluch Hernández, Angel Guerrero Zotano, et al.
Nature Cell Biology|April 21, 2018
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER<sup>+</sup> breast cancerSylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, et al.
Pageof 19